Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Apremilast did not work for treating severe alopecia areata.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

JAK inhibitors show promise in treating difficult skin diseases.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Oral baricitinib is effective and safe for treating alopecia areata.

Managing multiple autoimmune diseases in one patient is very challenging.

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.